December
06
/ 2019
In this interesting article entitled “A Faster, More Cost-Effective Alternative to Generic Bioequivalence”, Dr. Jag Shur, CEO of Nanopharm, an Aptar Pharma company, explores the challenges companies face in bringing generic respiratory and nasal therapies to market amidst a changing regulatory landscape. He explains the Aptar Pharma Services range for accelerating and derisking OINDP development, and introduces the CPhI 2019 Award winning SmartTrack™ as an alternative to bioequivalence studies.
Source url
display_title
Aptar Pharma and Nanopharm Featured in ONdrugDelivery’s Novembe...
Categories
Short Description
Paptar Pharma Is Featured In The November 2019 Edition Of Ondrugdelivery Magazine Which Focuses On Pulmonary Amp Nasal Drug Deliveryp